Mepolizumab for severe eosinophilic asthma.
摘要：
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year. Exacerbation rates at all doses were 50% less than those in the placebo group. There were no changes in any other asthma measures (symptoms, quality of life or lung function). This may be a useful advance for a subgroup of severe asthma with frequent exacerbations and persistent eosinophilia, which may be about half of severe asthmatics. More information on patient selection and cost-benefit will be required.
展开
DOI：
10.1586/ers.12.84
被引量：
年份：
2013
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
